• Wed, January 29, 2025

by: WOPRAI

Short squeeze is starting in shares of MONI at $0.017, after crossing above the $0.017 Trigger Price

by: AOL

3 ETFs Every Baby Boomer Should Buy and Hold Forever

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Retirement should be stress-free. You shouldn't have to worry about generating extra income.

by: Kiplinger

Stock Market Today: Stocks Jump Around on Fed Day

Fed Chair Jerome Powell plays it as straight as possible while President Trump and threats to the AI rally abound.

by: MSN

International Paper Company (IP): Investing in Renewable Packaging Innovation

We recently published a list of 35 Non-Tech AI Opportunities Amid DeepSeek Selloff. In this article, we are going to take a look at where International Paper Company (NYSE:IP) stands against other non-tech AI opportunities amid DeepSeek selloff.

by: MSN

UPS's SWOT analysis: global logistics giant navigates shifting stock landscape

United Parcel Service, Inc. (NYSE:UPS), the world's largest package delivery company, continues to navigate a complex and evolving global logistics landscape. With a vast network spanning over 220 countries and territories,

by: WOPRAI

Short squeeze is starting in shares of STKL at $7.545, after crossing above the $7.496 Trigger Price

by: Kiplinger

ASML Stock Remains a Strong Buy After Earnings

ASML stock rallied after the semiconductor supplier beat fourth-quarter expectations. Here's what you need to know.

by: WOPRAI

Short squeeze is starting in shares of TMQ at $1.29, after crossing above the $1.273 Trigger Price

by: MSN

DeepSeek and AI's Efficiency Era

Why software prowess and efficiency will be the major themes for AI in 2025. What to focus on when affected big tech companies report earnings this week. Then, Motley Fool Analyst David Meier interviews John Zahurancik,

by: MSN

Why Novo Nordisk A/S (NVO) Is the Best Blue Chip Stock to Buy Under $100?

We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best blue chip stocks to buy under $100.

by: WOPRAI

Short squeeze is starting in shares of PRMO at $0.04, after crossing above the $0.001 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of PPCB at $25, after crossing above the $0.003 Trigger Price

by: MSN

Looking for a bargain? 4 ways to tell if a stock is undervalued

Though you may not think of it the same way, investing in the stock market is no different. While people are typically excited to see their favorite items on sale at the grocery store, they can often be less enthusiastic when they see stock prices fall.

by: WOPRAI

Short squeeze is starting in shares of SNPMF at $0.57, after crossing above the $0.569 Trigger Price

by: MSN

Investing Lessons from Mark Cuban Anyone Can Use

Billionaire Mark Cuban has plenty of advice for the average person who wants to get rich and retire—but they may not want to hear it. Cuban made his money by building and selling tech companies and becoming an active stock trader.

by: MSN

US stocks, Nvidia shares steady after Chinese AI shock

US stocks and shares in chip-making giant Nvidia on Tuesday clawed back some of their losses following a sell-off triggered by the sudden success of Chinese artificial intelligence firm DeepSeek. General Motors reported a $3-billion quarterly loss Tuesday due to costs from restructuring a Chinese venture,

by: WOPRAI

Short squeeze is starting in shares of WKSP at $1.1, after crossing above the $1.077 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of ULCC at $8.25, after crossing above the $8.187 Trigger Price

by: MSN

Retire Rich With 2 Resilient Growth Stocks

Retiring rich and healthy is almost every Canadian's dream, but even though many of them save a significant sum, few can grow it into a sizable nest egg. The post Retire Rich With 2 Resilient Growth Stocks appeared first on The Motley Fool Canada.

by: MSN

5 Building Products Stocks Navigating Industry Challenges

The Zacks Building Products - Miscellaneous industry continues to navigate challenges stemming from a weak real estate market and inflation-driven consumer uncertainty. The real estate market remained weak due to high mortgage rates,

by: MSN

Cantor Fitzgerald sees upside in select biotech stocks

In a recent industry report focused on Biotechnology stocks, particularly those innovating in neurology and psychiatry, Cantor Fitzgerald highlighted a positive outlook despite broader market uncertainties.
  • Thu, January 30, 2025

by: Investopedia

Is Warren Buffett Right That the Stock Market Is Like a Casino? What Investors Need To Know

Warren Buffett's claim that the stock market is increasingly like a casino is supported by research. However, there are ways to shift the odds in your favor.

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Esports Entertainment Group, Inc. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Fox & Hound Restaurant Group in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Arizona Silver Exploration Inc. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Hepion Pharmaceuticals, Inc. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of ESGold Corp. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Sierra Madre Gold and Silver Ltd. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of IMAC Holdings, Inc. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Baijiayun Group Ltd in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Jayud Global Logistics Limited in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Aurora Mobile Limited in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Sharps Technology, Inc. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Almadex Minerals Ltd. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Nevada Canyon Gold Corp. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of CytoDyn Inc. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Evaxion Biotech A/S in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Dogwood Therapeutics, Inc. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Vincerx Pharma, Inc. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Bakkt Holdings, Inc. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Echo Defense Projects Inc. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of BioAdaptives, Inc. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Tapinator, Inc. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Hong Kong Technology Venture Company Limited in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Alpha Tau Medical Ltd. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of Foremost Lithium Resource & Technology Ltd. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of NeuroSense Therapeutics Ltd. in recent trading

by: WOPRAI

As of Jan 30th, 2025, there has been substantial selling of in recent trading

Cantor Fitzgerald sees upside in select biotech stocks

In a recent industry report focused on Biotechnology stocks, particularly those innovating in neurology and psychiatry, Cantor Fitzgerald highlighted a positive outlook despite broader market uncertainties.
The article from MSN Money discusses Cantor Fitzgerald's optimistic outlook on certain biotech stocks, highlighting potential growth opportunities within the sector. The investment firm has identified several biotech companies that they believe are undervalued and poised for significant upside due to upcoming catalysts such as clinical trial results, FDA approvals, and strategic partnerships. The article mentions specific stocks like Sarepta Therapeutics, Alnylam Pharmaceuticals, and Intellia Therapeutics as having strong potential due to their innovative therapies in gene editing and rare disease treatments. Cantor Fitzgerald's analysis suggests that these companies could see substantial stock price increases if their developmental milestones are met, offering investors a chance to capitalize on the biotech sector's volatility and innovation.

Read the Full MSN Article at:
https://www.msn.com/en-us/money/other/cantor-fitzgerald-sees-upside-in-select-biotech-stocks/ar-AA1y4j7H